Media stories about AcelRx Pharmaceuticals (NASDAQ:ACRX) have trended somewhat positive on Saturday, Accern reports. The research group identifies positive and negative news coverage by reviewing more than twenty million blog and news sources in real-time. Accern ranks coverage of publicly-traded companies on a scale of negative one to one, with scores closest to one being the most favorable. AcelRx Pharmaceuticals earned a media sentiment score of 0.07 on Accern’s scale. Accern also gave news articles about the specialty pharmaceutical company an impact score of 46.1778293835284 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the news articles that may have impacted Accern Sentiment’s analysis:
NASDAQ:ACRX traded up $0.05 on Friday, hitting $2.25. The company had a trading volume of 340,971 shares, compared to its average volume of 354,008. The company has a market cap of $111.98, a price-to-earnings ratio of -2.05 and a beta of 2.42. The company has a debt-to-equity ratio of -0.31, a current ratio of 4.64 and a quick ratio of 4.57. AcelRx Pharmaceuticals has a 52 week low of $1.55 and a 52 week high of $5.75.
AcelRx Pharmaceuticals (NASDAQ:ACRX) last issued its quarterly earnings data on Thursday, March 8th. The specialty pharmaceutical company reported ($0.20) EPS for the quarter, meeting the Thomson Reuters’ consensus estimate of ($0.20). The company had revenue of $0.74 million during the quarter, compared to the consensus estimate of $2.90 million. analysts expect that AcelRx Pharmaceuticals will post -0.98 EPS for the current year.
Separately, Zacks Investment Research upgraded shares of AcelRx Pharmaceuticals from a “hold” rating to a “buy” rating and set a $2.25 price target on the stock in a research report on Wednesday, December 27th. One investment analyst has rated the stock with a sell rating, four have issued a hold rating and four have given a buy rating to the company. AcelRx Pharmaceuticals presently has an average rating of “Hold” and a consensus target price of $4.92.
COPYRIGHT VIOLATION WARNING: This article was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are reading this article on another publication, it was copied illegally and reposted in violation of US & international copyright & trademark laws. The legal version of this article can be viewed at https://www.dispatchtribunal.com/2018/04/14/acelrx-pharmaceuticals-acrx-given-daily-news-impact-rating-of-0-07.html.
About AcelRx Pharmaceuticals
AcelRx Pharmaceuticals, Inc is a pharmaceutical company focused on the development and commercialization of therapies for the treatment of moderate-to-severe acute pain. The Company operates through the segment, which includes development and commercialization of product candidates for the treatment of pain.
Receive News & Ratings for AcelRx Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AcelRx Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.